CRL Feb 2023 190.000 put
| Previous close | 0.3100 |
| Open | 2.5000 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 190.00 |
| Expiry date | 2023-02-17 |
| Day's range | 2.5000 - 2.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 78 |
- GlobeNewswire
iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of
- Zacks
Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials
Charles River's (CRL) latest partnership is expected to bring a potentially curative therapy, RZ-001, to HCC patients.
- Zacks
Charles River (CRL) to Develop RNA-based Therapy With New Pact
Charles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients.
